Brazilian guideline for diagnosis and treatment of Chagas disease

ID: 

3084

Session: 

Poster session 3 Friday: Evidence Tools / Evidence synthesis - creation, publication and updating in the digital age

Date: 

Friday 15 September 2017 - 12:30 to 14:00

Location: 

Exhibition Halls 1 & 2

All authors in correct order:

Falavigna M1, Colpani V1, Cruz LN1, Stein C1, Sartori AMC2, de Sousa AS3, Camargo AMDA4, Moreira O5, de Melo EV6, Ebeidalla JSE6, Lima MM7, da Costa VM7, Gonçalves MR8, Gewehr-Filho PE1, Santos SME9, Marin-Neto JA10, Ribeiro ALP9, Polanczyk CA1
1 Hospital Moinhos de Vento, Brazil
2 Faculdade de Medicina da Universidade de São Paulo, Brazil
3 Faculdade de Medicina da Universidade Federal do Rio de Janeiro, Brazil
4 Universidade Estadual de Campinas, Brazil
5 Instituto Oswaldo Cruz Rio de Janeiro, Brazil
6 CONITEC/DGITS Ministério da Saúde, Brazil
7 DEVIT/SVS Ministério da Saúde, Brazil
8 Universidade Federal do Rio Grande do Sul, Brazil
9 Universidade Federal de Minas Gerais, Brazil
10 Universidade de São Paulo, Brazil
Presenting author and contact person

Presenting author:

Maicon Falavigna

Contact person:

Maicon Falavigna
Veronica Colpani
Abstract text
Background: Chagas disease is an infectious disease caused by the protozoan parasite Trypanossoma cruzi. It is estimated that 8 million people are chronically infected worldwide, especially in Latin America. However, its prevalence has increased outside endemic areas, such as USA and Europe, due to migration. Thirty to forty per cent of chronically infected patients develop Chagas cardiomyopathy or gastrointestinal disease, with clinical manifestations including heart failure and megaesophagus.

Objectives: To present the recommendations of the Brazilian guideline for diagnosis and treatment of Chagas disease.

Methods: The guideline development process followed the Guidelines International Network (G-I-N) and Institute of Medicine (IOM) standards and the G-I-N – McMaster Guideline Development Checklist. The guideline aimed to provide recommendations for diagnosis and treatment of Chagas disease, as requested by the Brazilian Ministry of Health. No high-quality guideline was available for adaptation or adoption. The scoping meeting was held in August 2016, with 15 panel members, including infection disease specialists, cardiologists, gastroenterologists, primary care physicians, biochemical, policy makers, health economists and patient representatives. No financial conflict of interest was reported by panel members. Seventeen clinical questions were defined for both acute and chronic phases, including special populations, such as pregnant women and immunosuppressed patients. An independent group of methodologists is responsible for evidence search and synthesis, including decision tree models for diagnostic tests.

Results: Evidence synthesis is currently in progress and the second guideline panel meeting will occur on March 2017. Results will be available for the Summit.

Conclusions: No high-quality evidence-based guideline for Chagas disease is available. This will be the first guideline for Chagas disease using the G-I-N and IOM standards. Although it has been developed for the Brazilian context, this guideline may be adopted by or adapted to other countries.